Ursodeoxycholic acid in primary sclerosing cholangitis: Meta-analysis of randomized controlled trials

Hepatology Research

Volumn 39, Issue 9, 2009, Pages 865-873

  Shi, Jian ^a   Li, Zhi ^a   Zeng, Xin ^a   Lin, Yong ^a   Xie, Wei Fen ^a  

^a SECOND MILITARY MEDICAL UNIVERSITY   (China)

Author keywords

Meta analysis; Primary sclerosing cholangitis; Ursodeoxycholic acid

Indexed keywords

COLCHICINE; PLACEBO; URSODEOXYCHOLIC ACID;

ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALKALINE PHOSPHATASE BLOOD LEVEL; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BILIRUBIN BLOOD LEVEL; BIOCHEMISTRY; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; DRUG MEGADOSE; DRUG SAFETY; FATIGUE; GAMMA GLUTAMYL TRANSFERASE BLOOD LEVEL; HUMAN; INCIDENCE; LIVER TRANSPLANTATION; META ANALYSIS; MORTALITY; OUTCOME ASSESSMENT; PRIMARY SCLEROSING CHOLANGITIS; PRIORITY JOURNAL; PRURITUS; RANDOMIZED CONTROLLED TRIAL; SENSITIVITY ANALYSIS; SIDE EFFECT; THERAPY EFFECT;

EID: 69949093564     PISSN: 13866346     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1872-034X.2009.00527.x     Document Type: Article

References (27)

1. Lee YM, Kaplan MM. Practice Guideline Committee of the ACG. Management of primary sclerosing cholangitis. Am J Gastroenterol 2002; 97: 528-34.
2. Burak K, Angulo P, Pasha TM et al. Incidence and risk factors for cholangiocarcinoma in primary sclerosing cholangitis. Am J Gastroenterol 2004; 99: 523-6.
3. Paumgartner G, Beuers U. Ursodeoxycholic acid in cholestatic liver disease: Mechanisms of action and therapeutic use revisited. Hepatology 2002; 36: 525-31.
4. Hayashi H, Higuchi T, Ichimiya H et al. Asymptomatic primary sclerosing cholangitis treated with ursodeoxycholic acid. Gastroenterology 1990; 99: 533-5.
5. Chazouilleres O, Poupon R, Capron JP et al. Ursodeoxycholic acid for primary sclerosing cholangitis. J Hepatol 1990; 11: 120-3.
6. Beuers U, Spengler U, Kruis W et al. Ursodeoxycholic acid for treatment of primary sclerosing cholangitis: A placebo-controlled trial. Hepatology 1992; 16: 707-14.
7. Stiehl A, Walker S, Stiehl L et al. Effect of ursodeoxycholic acid on liver and bile duct disease in primary sclerosing cholangitis. A 3-year pilot study with a placebo-controlled study period. J Hepatol 1994; 20: 57-64.
8. Mitchell SA, Bansi DS, Hunt N et al. A preliminary trial of high-dose ursodeoxycholic acid in primary sclerosing cholangitis. Gastroenterology 2001; 121: 900-7.
9. Lindor KD, for the Mayo Primary Sclerosing Cholangitis-Ursodeoxycholic Acid Study Group. Ursodiol for primary sclerosing cholangitis. N Engl J Med 1997; 336: 691-5.
10. Rost D, Rudolph G, Kloeters-Plachky P et al. Effect of high-dose ursodeoxycholic acid on its biliary enrichment in primary sclerosing cholangitis. Hepatology 2004; 40: 693-8.
11. Harnois DM, Angulo P, Jorgensen RA et al. High-dose ursodeoxycholic acid as a therapy for patients with primary sclerosing cholangitis. Am J Gastroenterol 2001; 96: 1558-62.
12. Cullen SN, Rust C, Fleming K et al. High dose ursodeoxycholic acid for the treatment of primary sclerosing cholangitis is safe and effective. J Hepatol 2008; 48: 792-800.
13. Jadad AR, Moore RA, Carroll D et al. Assessing the quality of reports of randomized clinical trials: Is blinding necessary? Control Clin Trials 1996; 17: 1-12.
14. Kjaergard LL, Villumsen J, Gluud C. Reported methodologic quality and discrepancies between large and small randomized trials in meta-analyses. Ann Intern Med 2001; 135: 982-9.
15. Moher D, Pham B, Jones A et al. Does quality of reports of randomised trials affect estimates of intervention efficacy reported in meta-analyses? Lancet 1998; 352: 609-13.
16. Shadish WR, Haddock CK. Combining estimates of effects size. In: Cooper H, Hedges LV, eds. The Handbook of Research Synthesis. New York: Russel Sage Foundation, 1994; 261-81.
17. DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials 1986; 7: 177-88.
18. Lo SK, Herrmann R, Chapman RW et al. Ursodeoxycholic acid in primary sclerosing cholangitis: A double-blind placebo controlled trial. Hepatology 1992; 16. 92A.
19. De Maria N, Colantoni A, Rosenbloom E et al. Ursodeoxycholic acid does not improve the clinical course of primary sclerosing cholangitis over a 2-year period. Hepatogastroenterology 1996; 43: 1472-9.
20. Bansi D, Christie J, Fleming K et al. High-dose ursodeoxycholic acid in primary sclerosing cholangitis: A randomized double-blind, placebo-controlled trial. Gastroenterology 1996; 110: 1146A.
21. Olsson R, Boberg KM, de Muckadell OS et al. High-dose ursodeoxycholic acid in primary sclerosing cholangitis: A 5-year multicenter, randomized, controlled study. Gastroenterology 2005; 129: 1464-72.
22. Shi J, Wu C, Lin Y et al. Long-term effects of mid-dose ursodeoxycholic acid in primary biliary cirrhosis: A meta-analysis of randomized controlled trials. Am J Gastroenterol 2006; 101: 1529-38.
23. Rudolph G, Kloeters-Plachky P, Rost D et al. The incidence of cholangiocarcinoma in primary sclerosing cholangitis after long-time treatment with ursodeoxycholic acid. Eur J Gastroenterol Hepatol 2007; 19: 487-91.
24. Goulis J, Leandro G, Burroughs A. Randomised controlled trials of ursodeoxycholic acid therapy for primary biliary cirrhosis: A meta-analysis. Lancet 1999; 354: 1053-60.
25. Gluud C, Christensen E. Ursodeoxycholicacid for primary biliary cirrhosis. Cochrane Database Syst Rev 2002; 1: CD000551.
26. Kaplan MM, Gershwin ME. Primary biliary cirrhosis. N Engl J Med 2005; 353: 1261-73.
27. Silveira MG, Lindor KD. Primary sclerosing cholangitis. Can J Gastroenterol 2008; 22: 689-98.